EPO and depressive symptom measurement: If the present trial reveals beneficial effects of Epo on mood and neurocognitive function in patients with treatment resistant depression and patients with remitted bipolar disorder, this would highlight Epo and its non-haematopoietic derivatives as candidate compounds for future 'cognitive enhancement' treatment strategies for affective disorders.